The 12 most common partnerships and co-selling mistakes and how to fix them for healthcare and life sciences in the DACH region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Every partnerships and co-selling failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: signing MOUs no one operationalises. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making sourced and influenced pipeline from partners the only weekly headline number.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Partnerships and co-selling works when one great partner is worth ten marketing hires; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.